Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
With blockbuster COVID-era earnings largely behind it, Pfizer is banking on newly built and acquired weight-loss efforts to offset major exclusivity losses coming in 2026 and 2027.
THE APEX TIMES
THE APEX TIMES
The Swedish developer of small-molecule candidates said it has entered an agreement with Eli Lilly (LLY) tied to an Alzheimer’s project, with financial and technical terms not detailed in the published market announcement.
THE APEX TIMES
Investors pushed Eli Lilly (LLY) higher after the company’s retatrutide program showed positive Phase 3 readouts presented at the American Diabetes Association meeting and published in The Lancet.
THE APEX TIMES
The company’s stock surged to a record level after it disclosed clinical trial results seen as favorable, reinforcing expectations for continued growth in the global obesity treatment market.
THE APEX TIMES
The investigational cancer vaccine, designed to prime the immune system against early precancerous growths, is set to open in spring or summer 2026 after UK ethics approval.
THE APEX TIMES
Eli Lilly announced agreements to buy Curevo, LimmaTech Biologics, and Vaccine Company, assembling a pipeline focused on shingles, bacterial pathogens, and Epstein-Barr virus using multiple vaccine platforms.
THE APEX TIMES
Eli Lilly has combined rapid sales growth from Mounjaro and Zepbound with new regulatory milestones and new go-to-market efforts, while also betting billions more on next-generation drugs through acquisitions.
THE APEX TIMES
In post-hoc data from two Phase 3 trials, women taking Foundayo (orforglipron) showed weight loss benefits in perimenopause and post-menopause, including results up to 30.4 pounds in one subgroup at the highest dose.
THE APEX TIMES
Eli Lilly reported new Phase 3 results for its investigational triple-agonist retatrutide, showing substantial weight reduction plus clinically meaningful improvements tied to obesity-related conditions. The market reaction helped lift the stock on June 8.
